Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Zymeworks Inc.
Type
Private
Industry Biotechnology
Founded 2003
Headquarters Vancouver, British Columbia, Canada
Key people
Ali Tehrani
Donald L. Drakeman
Products Pharmaceuticals
Number of employees
135 (35 PhDs)
Website www.zymeworks.com

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year.

This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric™ scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1. This scaffold can also be engineered with tailored effector function and optimized serum half-life. Bi-specific antibody therapeutics potentially allow drug-makers to combine two existing drugs used as a cocktail into one potent therapeutic.


Investment goal date:
Dividends reinvested
Zymeworks Inc. ZYME report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q3 2017
2017-11-08
-0.6400
0.0000
Q2 2017
2017-08-08
0.0000
0.0000
Q1 2017
2017-05-16
0.0000
0.0000
Q4 2016
2017-04-28
0.0000
0.0000
Q3 2017
1970-01-01
0.0000
0.0000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks